Jump to ContentJump to Main Navigation
Show Summary Details

Buchner, Johannes

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Sies, Helmut / Turk, Boris / Wittinghofer, Alfred

SCImago Journal Rank (SJR) 2015: 1.607
Source Normalized Impact per Paper (SNIP) 2015: 0.751
Impact per Publication (IPP) 2015: 2.609

See all formats and pricing



Select Volume and Issue


30,00 € / $42.00 / £23.00

Get Access to Full Text

Japanese encephalitis vaccines – needs, flaws and achievements

Erich Tauber1 / Shailesh Dewasthaly2

1Intercell AG, Campus Vienna Biocenter 2, A-1030 Vienna, Austria

2Intercell AG, Campus Vienna Biocenter 2, A-1030 Vienna, Austria

Corresponding author

Citation Information: Biological Chemistry. Volume 389, Issue 5, Pages 547–550, ISSN (Online) 14374315, ISSN (Print) 1431-6730, DOI: https://doi.org/10.1515/BC.2008.062, March 2008

Publication History

Published Online:


Japanese encephalitis causes serious health problems in countries in Southeast Asia, where the causative virus is endemic. Whereas most adults living in this region have acquired immunity, children are at high risk of infection. Childhood mass immunization programs with first-generation mouse brain-derived vaccines efficiently reduced Japanese encephalitis incidence in affected countries, but immunization recommendations have mostly been abolished in Japan owing to the occurrence of severe side effects. Thus, there is a pressing need for safer vaccines to keep the disease under control. The safety profile of the current vaccines, together with the relatively low incidence, makes the risk/benefit ratio unfavorable for immunization of travelers to Southeast Asia, despite the high mortality once the clinical disease has developed. As Asian countries become increasingly popular travel destinations, the availability of well-tolerated vaccines would likely shift the ratio towards immunization. Currently, there is one second-generation inactivated cell-culture-grown vaccine in late-stage clinical development that is approaching licensing in developed countries.

Keywords: flavivirus; IC51; immunogenicity; Southeast Asia

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Tobias E. Erlanger, Svenja Weiss, Jennifer Keiser, Jürg Utzinger, and Karin Wiedenmayer
Emerging Infectious Diseases, 2009, Volume 15, Number 1, Page 1

Comments (0)

Please log in or register to comment.